|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-19.20/-5.86
|
企业价值
7.13M
|
资产负债 |
每股账面净值
0.68
|
现金流量 |
现金流量率
--
|
损益表 |
收益
0
|
每股收益
0.73
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/05/18 00:40 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform. Harnessing the innate ability of GD-Ts has enabled the company to develop a range of clinical-stage cell therapies designed to combat cancer and viral infection. |